natgillin/translations-raw huggingface dataset:
The method according to claim 2, wherein said inflammatory bowel disease is selected from the group consisting of Crohn's disease and ulcerative colitis. 
Farmaceutski sastav u skladu s patentnim zahtjevom 12, pri čemu je navedena upalna bolest crijeva odabrana iz grupe koja se sastoji od Chronove bolesti i ulceroznog kolitisa.
[Paragraph 20] A pharmaceutical composition comprising the conjugate of paragraph 15. 
Farmaceutski sastav sadržeći konjugat iz spoja 15.
rapidly lowering the pH of the reaction mixture to a pH of less than 2 by addition of an acid; 
(ili) brzo snižavanje pH reakcijske smjese na pH od manje od 2 dodavanjem kiseline; pri čemu, izolirani monomerni kompleks platina (II) ima formulu | ili III:
The device according to claim 7, further comprising a pair of cutting device supports which are fixedly connected to the support frame or the table, wherein each cutting device is pivotally coupled by at least one hinge to a respective cutting device support for the purpose of setting the second angle. 
Uređaj prema patentnom zahtjevu 6, naznačen time što nadalje sadrži par nosača za rezni uređaj koji su fiksno spojeni na nosivi okvir ili stol, pri čemu je svaki rezni uređaj zakretno spojen s najmanje jednom šarkom na odgovarajući nosač reznog uređaja u svrhu postavljanja drugog kuta;
Apparatus according to claim 1, wherein the voltage is an a.c. sinusoid voltage and each codeword is formed by arranging a pre-set number of positive and negative half-waves of said a.c. sinusoid voltage according to a predetermined series. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što je napon izmjenični napon, a svaku kodnu riječ čini slaganje predodređenog broja pozitivnih i negativnih poluvalova navedenog izmjeničnog napona u skladu s predodređenim nizom.
Scheme B involves the Sandmeyer reaction of the 7-amino substituted quinazolin-4-one compound of formula 3 which was prepared as set forth in Scheme A, with concentrated sulphuric acid and sodium nitrite to obtain the 7-hydroxy substituted quinazolin-4-one compound of formula 4. 
Shema B uključuje Sandmeyerovu reakciju 7-amino supstituiranog kinazolin-4-ona, spoja formule 3, koji je dobiven na način prikazan u shemi A, s koncentriranom sumpornom kiselinom 1 natrijevim nitritom, čime se dobije 7-hidroksi supstituirani kinazolin-4-on, spoj formule 4.
The bispecific IgG antibody according to claim 1, wherein both arms comprise a common light chain. The bispecific IgG antibody according to any one of claims 1-2, wherein the arm that specifically recognizes CLEC12A or a functional equivalent thereof comprises a heavy chain CDR1 sequence consisting of a sequence that is at least 90% identical to SGYTFTSY and a heavy chain CDR2 sequence consisting of a sequence that is at least 90% identical to IINPSGGS and a heavy chain CDR3 sequence consisting of a sequence that is at least 90% identical to GTTGDWFDY. 
Bispecifično humano IgG protutijelo pune dužine, naznačeno time, što navedeno bispecifično IgG protutijelo sadrži jednu granu koja specifično prepoznaje CLEC12A i drugu granu koja specifično prepoznaje CD3, i pri čemu grana koja specifično prepoznaje CLEC12A sadrži varijabilnu sekvencu teškog lanca koja se sastoji od sekvence identičnoj s QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGG STSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAKGTTGDWFDYWGQGT LVTVSS; ili varijabilnu sekvencu teškog lanca koja se sastoji od sekvence identičnoj s i pri čemu obje grane sadrže zajednički laki lanac koji sadrži varijabilnu sekvencu lakog lanca koja se sastoji od sekvence identičnoj s
In a corresponding manner, the invention also relates to a method for decoding a data signal representative of at least one image split up into partitions which has been previously coded, a current partition to be decoded containing data at least one data item of which is allotted a sign. Such a decoding method is noteworthy in that it comprises, for the current partition, the following steps: 
Postupak dekodiranja reprezentativnog signala podataka barem jedne prethodno kodirane slike podijeljene u particije, jedne trenutne particije Bi za dekodiranje koja sadrži podatke pri čemu je barem jednom podatku dodijeljen predznak, a podaci su koeficijenti direktne transformacije, te je navedeni postupak dekodiranja naznačen time da se za trenutnu particiju provode slijedeći koraci:
A compound, pharmaceutically acceptable salt thereof or composition according to claim 5, for use in treatment of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Spoj, njegova farmaceutski prihvatljiva sol ili smjesa prema zahtjevu 5, za uporabu u liječenju bolesti ili stanja izabranih između; emocionalna nestabilnost; o pseudobulbarni afekt; autizam; neurološki poremećaji; neurodegenerativne bolesti; ozljeda mozga; poremećaji svijesti; kardiovaskularne bolesti; glaukom; tardivna diskinezija; dijabetička neuropatija; retinopatijske bolesti; bolesti ili poremećaji uzrokovani apoptozom koja je inducirana homocisteinom; bolesti ili poremećaji uzrokovani povišenim razinama homocisteina; kronična bol; intraktabilna bol; neuropalska bol; bol posredovana simpalikusom; bol povezana s disfunkcijom probavnog suslava; epileptički napadaji; tinitus; seksualna disfunkcija; intraktabilni kašalj; dermatitis; poremećaji ovisnosti; Rettov sindrom (RTT); poremećaji glasa uslijed nekontroliranog grčenja mišića larinksa; neurotoksičnost metotreksata; i umor uzrokovan rakom.
Element according to any of the preceding claims, wherein at least one of the inspection channels (6-8) is oriented perpendicular with respect to a side wall (1,2). 
Sustav za prihvat tekućina u skladu s patentnim zahtjevom 3, naznačen time što otvori na bočnim stijenkama (11-13) su poravnani s vodoravno položenim kanalom (6-8).
The composition of claim 14, characterized in that it further comprises one agent as a combination product for simultaneous, separate or sequential use, and wherein said agent is an antibody selected between anti-IGF-IR, anti-EGFR, anti-HER2/neu, anti-VEGFR, and anti-VEGF, antibodies. 
Pripravak iz patentnog zahtjeva 14, naznačen time da dalje sadrži jedno sredstvo kao kombinacijski produkt za istodobnu, odvojenu ili uzastopnu upotrebu, pri čemu rečeno sredstvo jest antitumorsko antitijelo.
For most practical purposes, only the free energies from the particle bulk and the particle surface need to be considered. 
Za najpraktičnije svrhe je potrebno razmatrati slobodne energije samo od množine čestica i površine čestica.
Brief Description of the Drawing 
Kratki opis crteža
on the effect of sub-chronic PCP (2mg/kg, i.p twice daily for seven days) treatment on the discrimination index (DI). 
na učinak sub-kroničnog PCP (2mg/kg, i.p dva puta dnevno tijekom sedam dana) tretiranja pomoću indeksa diskriminacije (DI).
A method according to any one of the claims 1 to 3, characterised in that, after having applied said magnetic particles onto the cysts, the cysts have a water content of less than 25 wt. %, preferably of less than 20 wt. %, or they are dried to a water content of less than 25 wt. %, preferably of less than 20 wt. % and more preferably of less than 15 wt. %. 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time što nakon primjene magnetskih čestica na ciste, ciste imaju sadržaj vode manji od 25 te2%, poželjno manje od 20 tež%, ili su osušene tako da je sadržaj vode manji od 25 tež%, poželjno manji od 20 tež% i još poželjnije manji od 15 tež%.
Apparatus according to claim 3, comprising a processor arranged to receive data from the flatness measuring device (9) and to control the heating devices (8) and, or the cryogenic fluid applicators (7) responsive to the data, thereby varying the application of heat and, or cryogenic fluid to the one or more zones. 
Uređaj prema zahtjevu 3, naznačen time, da sadrži procesor podešen za primanje podataka iz sredstva za mjerenje plosnatosti (9) i za upravljanje s grijaćim napravama (8) i, ili s aplikatorima kriogene tekućine (7) kao odgovor na podatke, čime se primjenjuje različita količina topline 1, ili kriogene tekućine na jedmu ili više zona.
posaconazole, wherein posaconazole is selected from crystalline form I or II of posaconazole; 
(i) posakonazola, pri čemu je posakonazol odabran od kristalnog oblika I ili I posakonazola ili njihove mješavine;
• the heat induced crystallinity is of from 16% to 24%, 
. toplinom inducirana kristalnost je od 16% do 24%, .
a zone further downstream than the zone of horizontal parking or pre-assembly, to evacuate finished products; and 
5) zonu još dalje nizvodno (42) od zone (41) za parking ili prethodno sklapanje, za odvođenje gotovih proizvoda;
reacting an intermediate of formula (VI') wherein W3 represents a suitable leaving group, with an intermediate of formula (XIII) in the presence of CO, a suitable catalyst, a suitable ligand, a suitable base, and a suitable solvent, With R1, R2, R1a and n as defined in claim 1; 
reakcija intermedijera formule (VI’) gdje W3 predstavlja prikladnu odlazeću skupinu, s intermedijerom formule (XIII) u prisutnosti CO, prikladnog katalizatora, prikladnog liganda, prikladne baze, i prikladnog otapala, [image] s R1, R2, R1a i n kako su definirani u zahtjevu 1;
wherein * indicates the point of attachment of said group with the rest of the molecule; and represents a substituent selected from: a halogen atom, C1-C6-alkoxy- group, C1-C6-alkyl- group; 
; pri čemu * označava točku vezanja navedene skupine s ostatkom molekule; i R3 predstavlja supstituent odabran iz skupa koji sadrži: halogeni atom, skupinu C;-Cs-alkoksi-, skupinu Cy-Cg-alkil-;
The tablet or capsule as defined in any one of claims 1-3, wherein the particles have a D90 equal to or less than 50 µm as measured by laser light scattering. 
granulacije sirovih materijala iz koraka (1) primjenom procesa suhe granulacije, pri čemu čestice kristalnog apiksabana imaju D90 manji od 89 µm, kao što je mjereno laserskim raspršivanjem svjetlosti;
Combination as claimed in claim 8 and any of the claims 4-7, wherein the drain is arranged in the opening in the tile. 
Kombinacija u skladu s patentnim zahtjevom 5 1 bilo kojim od patentnih zahtjeva 1-4, naznačena time što se ispust (16; 44; 53) nalazi u otvoru u obložnoj pločici.
Pharmaceutical preparations for the combination therapy for enteral or parenteral administration are, e.g., those in unit dosage forms, such as tablets including sugar-coated tablets, capsules, suppositories and ampoules. 
Farmaceutski pripravci za kombiniranu terapiju za enteralno ili parenteralno davanje jesu npr. pripravci u oblicima za jedinično doziranje, kao što su tablete uključivo tablete prevučene sa šećerom, kapsule, čepići i ampule.
a halogenated heteroaromatic group and a nucleophile; optionally wherein the halogenated heteroaromatic group is selected from the group consisting of chlorinated pyrimidines, chlorinated triazines and chlorinated purines; or wherein the nucleophile is an amino group. 
halogeniranu heteroaromatsku grupu i nukleofil; po izboru se halogenirana heteroaromatska grupa izabire iz skupine koja obuhvaća klorirane pirimidine, klorirane triazine i klorirane purine; ili gdje je nukleofil amino skupina.
Universal and rapid covering system according to claim 1, wherein said cover (1) is provided with a back opening (36) as to allow access to the object covered any time and without any difficulties. 
Univerzalan 1 brz sustav prekrivanja prema zahtjevu 1, pri čemu navedeni prekrivač (1) sadrži stražnji otvor (36), a radi omogućavanja pristupa prekrivenom predmetu u svakom trenutku i bez ikakvih poteškoća.
In some additional embodiments, the improved property of the engineered polypeptides having phenylalanine ammonia lyase activity (PAL) is selected from reduced sensitivity to proteolysis and/or increased tolerance to acidic pH. 
(iv) da je poboljšana osobina odabrana od reducirane osjetljivosti na proteolizu 1/ili povećane tolerancije na kiselu pH.
reacting a compound of formula (iv′) with carbon disulfide so as to obtain a compound of Formula I′ 
reakciju spoja formule (iv) s ugljičnim disulfidom da bi se dobio spoj Formule Ib:
According to one embodiment the renewable oil or renewable fuel may be emulsified with a petroleum fraction based fuel then introduced into the refinery process. 
Postupak prema jednom od prethodnih zahtjeva, naznačen time što frakcija petroleja sadrži teško plinsko ulje ili sirovinu teško-srednjeg destilata.
An oligonucleotide according to claim 1, comprising one or more RNA residues, and/or one or more DNA residues. 
2. |< Oligonukleotid u skladu s patentnim zahtjevom 1, naznačen time što sadrži ostatke RNA, ili jedan ili više ostataka DNA.
The chill chamber 2 is provided with a lid 5 that is attached to a side wall of the chill chamber 2 at a hinge point 6 such that it can hinge. 
Hladna komora 2 ima poklopac 5 koji je pričvršćen na bočnu stjenku hladne komore 2 pomoću šarke 6, tako da se pomoću te iste šarke može otvoriti.
In particular, the invention provides: the 2 S,3 S,11b R isomer of 3,11b- cis -dihydrotetrabenazine having the formula (Ia): 
Četiri izomera su bila izolirana i okarakterizirana 1 imaju slijedeće strukture: HR P20080677 T3 (a) 25,35,11bR izomer 3,11b-cis-dihidrotetrabenazina ima formulu (Ia):
The pharmaceutical composition according to any preceding claim wherein the pharmaceutically acceptable salt of glycopyrrolate is selected from fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, benzoate, p-chlorobenzoate, diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, p-hydroxybenzoate, 1 -hydroxynaphthalene-2- carboxylate, 3-hydroxynaphthalene-2-carboxylate, methanesulfonate and benzenesulfonate. 
Ko-suspenzija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se farmaceutski prihvatljiva sol glikopirolata bira između fluorida, klorida, bromida, jodida, nitrata, sulfata, fosfata, formijata, acetata, trifluoracetata, propionata, butirat, laktata, citrata, tartarata, malata, maleata, sukcinata, benzoata, p- klorbenzoata, difenilacetata ili trifemilacetata, o-hidroksibenzoata, p-hidroksibenzoat, 1-hidroksinaftalen-2-karboksilata, 3-hidroksinaftalen-2-karboksilata, metansulfonata i benzensulfonata.
a compound wherein R1 is a hydrogen atom, methyl group, ethyl group, propyl group, isopropyl group, tert-butyl group or hexyl group, 
Medicinska oftalmološka otopina za uporabu prema Zahtjevu 1, gdje R' predstavlja atom vodika, metil skupinu, etil skupinu, propil skupinu, izopropil skupinu, fert-butil skupinu ili heksil skupinu,
a mattress support (2), joined to the furniture frame (4) and having a support surface (8) positioned on a base plane (X); 
- < nosač (2) namještaja, koji je spojen s postoljem (4) namještaja i ima noseću površinu (8) postavljenu na osnovnoj ravnini (X);
A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 1 to 8. 
Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljive nosače i kao aktivnu supstancu terapeutski učinkovitu količinu spoja prema zahtjevima 1 do 8,
Cortexolone-17a-propionate in hydrate crystalline form IV according to any one of claims 21 to 22 for use in treating acne, seborrhoeic dermatitis, androgenic alopecia, hirsutism, benign prostatic hyperplasia, forms of prostate cancer, polycystic ovary syndrome, syndrome of precocious puberty and control of aggressive or aberrant sexual behaviors. 
Farmaceutski pripravak za primjenu prema patentnom zahtjevu 4 za liječenje akni, seboreičnog dermatitisa, androgenetske alopecije, hirzutizma, benigne hiperplazije prostate, oblika raka prostate, sindroma policističnih jajnika, sindroma preranog puberteta i kontrole agresivnog ili aberantnih seksualnih ponašanja.
in the form of a salt, such as a hydrohalide, in the presence of an inorganic base, such as NaH or an organic base, such as BEMP, e.g., in a polar aprotic solvent, such as N,N-DMF; the reaction may be carried out at 10-40° C., conveniently at ambient temperature. 
R?in su definiran kao ovdje ranije, u obliku soli, kao što je hidrohalogenid, u prisutnosti anorganske baze, kao što je NaH ili organske baze, kao što je BEMP, npr. u polarnom aprotonskom otapalu, kao što je N,N-DMF; reakciju se može provesti pri 10-40"C, prikladno pri sobnoj temperaturi.
Some embodiments include pharmaceutical compositions comprising: (a) a safe and therapeutically effective amount of the indazole, or its corresponding enantiomer, diastereoisomer or tautomer, or pharmaceutically acceptable salt; and (b) a pharmaceutically acceptable carrier. 
Na <Tz. ili njegova farmaceutski prihvatljiva sol. Farmaceutski pripravak, naznačen time da sadrži terapeutski učinkovitu količinu spoja prema zahtjevu 1, ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljivu pomoćnu tvar.
The malonate salt according to claim 1, which is the hydrogen malonate salt of the compound of formula (I). 
Sol malonata prema zahtjevu to je vodik malonska sol spoja formule (I).
An anti-IL-1B antibody or IL-1B-binding fragment thereof for use of claims 1-5, wherein administration of an initial dose of the antibody or antibody fragment is followed by the administration of one or more subsequent doses, and wherein said one or more subsequent doses are in an amount that is approximately the same or less than the initial dose. 
Anti-IL-1B protutijelo ili njegov IL-1B-vezujući fragment za uporabu prema zahtjevima 1-5, gdje nakon primjene početne doze protutijela ili fragmenta protutijela slijedi primjena jedne ili više sljedećih doza, i gdje je ta jedna ili više sljedećih doza u količini koja je otprilike jednaka ili manja od početne doze.
A winch according to claim 3 or claim 4 wherein, when the crank handle is located in the drive socket, the motor can be driven in a reverse-winding direction, and non-reverse winding of the winch drum is indicated to the operator by an audible signal. 
Vitlo prema zahtjevu 1 ili zahtjevu 2, naznačeno time, da kada je zahvatna ručica smještena u pogonskom grlu, elektromotor se može pogoniti u smjeru povratnog okretanja namatanja, a ne-povratno okretanje namatanja bubnja vitla, naznačava se korisniku pomoću zvučnog signala.
The composition according to Embodiment 98, wherein the composition comprises microcystalline cellulose and starch in a weight ratio ranging from about 1:1 to about 15:1. The composition according to Embodiment 106, wherein the composition comprises microcystalline cellulose and starch in a weight ratio of about 10:1. The composition according to Embodiment 98, wherein the granules within the composition comprises microcystalline cellulose and starch in a weight ratio ranging from about 1:1 to about 10:1. 
Smjesa prema zahtjevu 1, gdje smjesa sadrži mikrokristaliničnu celulozu i škrob u težinskom omjeru u rasponu od 1:1 do 15:1, poželjno u težinskom omjeru od 10:1. Smjesa prema zahtjevu 11 ili 28, gdje granule u smjesi sadrže mikrokristaliničnu celulozu i škrob u težinskom omjeru u rasponu od 1:1 do 10:1, poželjno je težinski omjer 5:1.
The apparatus according to one of Claims 5 to 14, characterized in that the second insulator comprises an extraction facility. 
Uređaj prema jednom od Zahtjeva 5 do 14, naznačen time da drugi izolator sadržava jedinicu za ekstrakciju.
In a further embodiment of the invention there is provided a mushroom production process further comprising the steps of monitoring the temperature of the heated liquid in the buffer tank and maintaining the temperature of the heated liquid in the buffer tank at a desired temperature. 
Postupak prema zahtjevu 8 gdje taj postupak obuhvaća korake praćenja temperature zagrijane tekućine u međuspremniku i održavanje temperature zagrijane tekućine u međuspremniku na željenoj temperaturi.
thoroughly washing a porcine-isolated tendon/sinew tissue with distilled water and ethanol, followed by storage at -20°C; 
temeljitog ispiranja tkiva tetive/ligamenta izoliranog od svinje s destiliranom vodom i etanolom, te potom pohranjivanja na -20°C;
The mixture was evaporated in vacuo and the product purified by column chromatography on silica gel using ethyl acetate as an eluent. 
Smjesa je evaporirana in vacuo i proizvod purificiran stupom kromatografije na silikonskom gelu korištenjem etil acetata kao eluenta.
The method of any of claim 1 to 12, wherein the conditionally male sterile phenotype and/or the Ms allele is linked to and/or associated with one or more of the characteristics selected from the group consisting of a phenotype of bud abortion in a plant with a male sterile phenotype referred by the Ms allele, and a phenotype of white-striped or white blotched petals in a plant with a male sterile phenotype referred by the Ms allele, and 
Postupak prema bilo kojem od zahtjeva 1 do 9, naznačen time da uvjetovani muški sterilni fenotip i/ili Ms alel je vezan na i/ili udružen sa jednom ili više značajki odabranih iz skupine koja se sastoji od I. fenotipa od odbačenih pupoljaka kod biljke sa muškim sterilnim fenotipom koji je posredovan sa Ms alelom, II. fenotipa bijelo-prugastih ili bijelo-pjegavih latica kod biljke sa muškim sterilnim fenotipom koji je posredovan sa Ms alelom, i
an OX40 agonist antibody. 
(vi) OX40 agonističkog antitijela.
The compound according to claim 1 or the pharmaceutical composition of claim 2 for use in treating allograft transplant rejection in a transplant recipient. 
Spoj ili farmaceutski pripravak za uporabu prema zahtjevu 4, naznačen time da je za uporabu kod liječenja odbacivanja presatka kod primatelja presatka.
The signal frame is converted into a time domain according to an OFDM scheme (S160) 
Okvir signala je prelvoran u vremensku domenu prema OFDM shemi,
GRN163L for use in the treatment of cancer according to claim 1, wherein said treatment consists of administration of at least about 6.2 mg/kg. 
Postupak prema zahtjevu 4, pri čemu je neželjena reakcija stupanj 3 ili 4 trombocitopenije. Postupak prema zahtjevu 1, pri čemu terapija inhibicijom telomeraze obuhvaća davanje inhibitora telomeraze za liječenje raka.
a microwave generator; 
mikrovalni generator (56);
The compounds of the invention described above (proteins, peptides, organic compounds) can be used as anti-disease associated with uncontrolled FGF2-dependent proliferation of fibroblasts or smooth muscular cells, cicatrization linked to excessive fibroblastic response, and restenosis after angioplastic. 
Peptid u skladu s patentnim zahtjevima 1 do 4, naznačen time što je namijenjen upotrebi protiv bolesti povezane s nekontroliranom proliferaciji fibroblasta ili stanica glatkih mišića ovisnoj o FGF2, cikatrizacijom povezanom s prekomjernim odgovorom fibroblasta, te restenozom nakon angioplastike.
The variant of any preceding claim, wherein the reference anti-TNF-a antibody or reference anti-TNF-a binding fragment comprises a variable heavy chain fragment having an amino acid sequence corresponding to SEQ ID NO:2 and a variable light chain fragment having an amino acid sequence corresponding to SEQ ID NO:4. 
Varijanta iz bilo kojeg od prethodnih patentnih zahtjeva, naznačena time, da referentno anti-TNF-a, antitijelo ili fragment koji se veže referentnog anti-TNF-o antitijela sadržava varijabilni fragment teškog lanca koji ima aminokiselinsku sekvenciju koja odgovara SEQ ID NO:2 i varijabilni fragment lakog lanca koji ima aminokiselinsku sekvenciju koja odgovara SEQ ID NO:4.